The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
Genta Iwamoto,Takashi Kawahara,Takashi Kawahara,Yumiko Yokomizo,Yasuhide Miyoshi,Masahiro Yao,Hiroji Uemura +6 more
1
TL;DR: The present study was the first to examine the NLR over the course of treatment in the samemHSPCpatientcohort, when the PSA level was at its nadir, and when they developed CRPC status.
read more
About: This article is published in Asian Journal of Urology. The article was published on 07 Sep 2021. and is currently open access. The article focuses on the topics: Prostate cancer & Neutrophil to lymphocyte ratio.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.
Takashi Kawahara,Masashi Kato,Ken-ichi Tabata,Ippei Kojima,Hiroshi Yamada,Osamu Kamihira,Hideyasu Tsumura,Masatsugu Iwamura,Hiroji Uemura,Yasuhide Miyoshi +9 more
TL;DR: A higher NLR was associated with a poorer OS for CRPC patients who received ABI or ENZ and was positively correlated with prostate cancer progression.
References
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Karim Fizazi,Nam Phuong Tran,Luis Fein,Nobuaki Matsubara,Alfredo Rodríguez-Antolín,Boris Alekseev,Mustafa Ozguroglu,Dingwei Ye,Susan Feyerabend,Andrew Protheroe,Peter De Porre,Thian Kheoh,Youn C. Park,Mary B. Todd,Kim N. Chi +14 more
TL;DR: The addition of abiraterone acetate and prednisone to androgen‐deprivation therapy significantly increased overall survival and radiographic progression‐free survival in men with newly diagnosed, metastatic, castration‐sensitive prostate cancer.
1.9K
Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients
Xiaobin Gu,Xianshu Gao,Xiaoying Li,Xin Qi,Mingwei Ma,S. Qin,Hao Yu,Shaoqian Sun,Dong Zhou,Wen Wang +9 more
TL;DR: Stratified analysis by PCa type, sample size, ethnicity and NLR cut-off value revealed that NLR showed consistent prognostic value in metastatic castration-resistant prostate cancer patients and predict poor PFS/RFS in Asians, but not in Caucasians.
127
Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non–muscle-invasive Urothelial Bladder Cancer
Francesco Cantiello,Giorgio Ivan Russo,Mihai Dorin Vartolomei,Mihai Dorin Vartolomei,Mihai Dorin Vartolomei,Abdal Rahman Abu Farhan,Daniela Terracciano,Gennaro Musi,Giuseppe Lucarelli,Savino M. Di Stasi,Rodolfo Hurle,Vincenzo Serretta,Gian Maria Busetto,Chiara Scafuro,Sisto Perdonà,Marco Borghesi,Riccardo Schiavina,Antonio Cioffi,Ettore De Berardinis,Gilberto L. Almeida,Pierluigi Bove,Estevão Lima,Giuseppe Ucciero,Deliu Victor Matei,Nicolae Crisan,Paolo Verze,Michele Battaglia,Giorgio Guazzoni,Riccardo Autorino,Giuseppe Morgia,Rocco Damiano,Ottavio De Cobelli,Vincenzo Mirone,Shahrokh F. Shariat,Shahrokh F. Shariat,Matteo Ferro +35 more
TL;DR: A risk score based on the measurement of routine systemic inflammatory markers can identify patients with high-grade bladder cancer not invading the muscular layer who are more likely to suffer from tumor recurrence and progression and could be used to select patients who might benefit from early bladder removal.
83
Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer.
Takashi Kawahara,Yumiko Yokomizo,Yusuke Ito,Hiroki Ito,Hitoshi Ishiguro,Jun Ichi Teranishi,Kazuhide Makiyama,Yasuhide Miyoshi,Hiroshi Miyamoto,Masahiro Yao,Hiroji Uemura +10 more
TL;DR: Pretreatment NLR may function as a new biomarker that precisely predicts the prognosis in patients with metastatic prostate cancer.
Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance.
TL;DR: NLR is a predictor of GS upgrading and BCR, but not disease upstaging in patients with low-risk PCa, and higher NLR was found to be associated with higher GS PCa.